CIRB Studies
Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
| Study Number | Lead Group | Study Title | CIRB | Study Status |
|---|---|---|---|---|
| AAML1421 | COG | A Phase 1/2 Study of CPX-351 (NSC# 775341; IND #129443) Alone Followed by Fludarabine; Cytarabine; and G-CSF (FLAG) for Children with Relapsed Acute Myeloid Leukemia (AML) | Pediatric CIRB | Available to Open |
| 10096 | ETCTN | A Phase 1/2 Study of Combination Olaparib and Radium-223 in Men with Metastatic Castration-Resistant Prostate Cancer with Bone Metastases (COMRADE) | Adult CIRB - Early Phase Emphasis | Available to Open |
| AHOD1221 | COG | A Phase 1/2 Study of Brentuximab Vedotin (SGN35; IND# 117117) in Combination with Gemcitabine for Pediatric and Young Adult Patients with Relapsed or Refractory Hodgkin Lymphoma | Pediatric CIRB | Completed |
| 10551 | ETCTN | A Phase 1/1b Study of Anti-CD47 Hu5F9-G4 (Magrolimab) in Combination with Olaparib in Patients with BRCA1/2-mutant Tumors | Adult CIRB - Early Phase Emphasis | Available to Open |
| 10422 | ETCTN | A Phase 1/1b Dose Escalation Study of Abemaciclib and Olaparib for Recurrent Platinum-Resistant Ovarian Cancer | Adult CIRB - Early Phase Emphasis | Available to Open |
| 10440 | ETCTN | A Phase 1/1a Study of Venetoclax, MLN9708 (ixazomib citrate) and Dexamethasone for Relapsed/Refractory Light Chain Amyloidosis | Adult CIRB - Early Phase Emphasis | Available to Open |
| PEPN2112 | COG | A Phase 1/ 2 Study of BAY 1895344 (elimusertib, IND#152153, NSC#810486) in Pediatric Patients with Relapsed or Refractory Solid Tumors | Pediatric CIRB | Available to Open |
| 10349 | ETCTN | A Phase 1 Trial of the p97 Inhibitor CB-5339 in Patients With Advanced Solid Tumors and Lymphomas | Adult CIRB - Early Phase Emphasis | Completed |
| 9899 | ETCTN | A Phase 1 Trial of the Combination of the Heat Shock Protein-90 (HSP90) inhibitor Onalespib (AT13387) and the Cyclin-Dependent Kinase (CDK) inhibitor AT7519M in patients with Advanced Solid Tumors | Adult CIRB - Early Phase Emphasis | Completed |
| PEPN1812 | PEP-CTN | A Phase 1 Trial of the CD123 X CD3 DART® Molecule Flotetuzumab (NSC#808294, IND#145986) in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia | Pediatric CIRB | Available to Open |